CRISPR sickle cures work remarkably well, yet millions worldwide still cannot reach them safely.
Gene editing for sickle cell disease is one of the most real “future medicine” stories alive right now. The science works far better than many people expected.
Doctors collect blood stem cells, edit them outside the body, then put them back so the patient starts making more fetal hemoglobin. That helps stop the red cells from sickling and damaging organs.
The problem is scale. Current treatment needs specialized hospitals, chemotherapy, long recovery time, and a price tag most of the world cannot touch.
For Americans, this is a warning too: even breakthrough cures can become elite medicine if delivery stays too hard and too expensive.
Should a cure still count as progress if only a tiny fraction can get it?